News
28 July 2022
CANTAB to be used in US Department of Defense PTSD trial
We are pleased to announce two agreements in a new therapeutic area for Cambridge Cognition, post-traumatic stress disorder ("PTSD"). Most recently, a research agreement was entered into with the United States Department of Defense, following on from a contract secured earlier this year with a top 10 pharmaceutical company.
Read on
18 July 2022
Join us at AAIC 2022
We are looking forward to attending this year’s Alzheimer’s Association International Conference (AAIC) in San Diego from 31st July to 4th August and learning about the latest developments in dementia research.
Read on
14 July 2022
2022 CANTAB Research Grant winners announced
It has been another highly competitive year for our CANTABTM Research Grant, with the large number of high-quality applications making picking just three winners a challenge for our judging panel! Here we reveal the winning grants.
Read on
31 May 2022
Cambridge Cognition partners on ambitious project for digital measurement of Alzheimer’s disease and related dementia symptoms
Cambridge Cognition is pleased to announce that they have joined the Digital Medicine Society’s (DiMe) Alzheimer’s Disease and Related Dementias (ADRD) Digital Measure Development project. As a partner of this innovative, collaborative effort, Cambridge Cognition will work to harness the potential of digital medicine to advance therapies for ADRD.
Read on
13 May 2022
Investigating the Impact of COVID-19 on Cognition
Children of the 90s collaborates with researchers at Cambridge Cognition to investigate the cognitive impacts of COVID-19.
Read on
16 December 2021
Electronic Clinical Outcomes Assessment contract win worth over £500,000
Cambridge Cognition is pleased to announce that it has won a contract worth over £500,000 to provide electronic clinical outcome assessments ("eCOA").
Read on
9 December 2021
Cambridge Cognition wins £1.0m schizophrenia clinical trial contract
Cambridge Cognition, which develops and markets digital solutions to assess brain health, is pleased to announce that it has secured a contract for an additional schizophrenia clinical trial worth £1.0m.
